Global Genomic Biomarker Market, by Indication (Oncology, Cardiovascular diseases, Neurological diseases, and Others), by End User (Hospitals, Diagnostic & Research Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,396.6 million in 2021, and is expected to exhibit a CAGR of 9.5% during the forecast period (2021-2028).
Rising instances of chronic diseases, for example, disease, coronary episodes, stroke, and others are supposed to drive the development of the global genomic biomarker market during the gauge time frame. For example, as indicated by information given by the Cancer Research U.K, in 2018, in excess of 17 million new disease cases were accounted for across the globe. Additionally, as indicated by the Global Burden of Disease (GBD) Study 2019, the predominant number of instances of cardiovascular diseases across the globe was around 523 million.
𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 𝐭𝐨 𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 (𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐎𝐟𝐟𝐞𝐫: 𝐔𝐩 𝐭𝐨 𝟑𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐟𝐨𝐫 𝐀 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 𝐓𝐢𝐦𝐞) @ https://www.coherentmarketinsights.com/insight/request-sample/4578
Market players are occupied with inorganic exercises, for example, acquisitions of organizations, as most would consider being normal to drive the development of the genomic biomarker market. For example, in October 2019, Qiagen, a German atomic diagnostic innovation supplier, entered a long-term organization with Illumina Inc., an American biotechnology organization, to foster mechanically progressed diagnostic strategies in light of genomic analysis.
Global Genomic Biomarker Market – Impact of Coronavirus (COVID – 19) Pandemic
Coronavirus flare-up was first covered on December 31, 2019, in Wuhan, China. As indicated by WHO, over 177 million cases and 3.8 million deaths because of Coronavirus (COVID-19) were accounted for up till June 20, 2021, across the globe.
The COVID-19 pandemic has impacted a few markets across the globe and is additionally expected to hamper the demand and supply in the global genomic biomarker market. The COVID-19 pandemic has impacted the demand and supply of the genomic biomarker market in three principle ways; by straightforwardly influencing the creation and demand; by making disturbances in dissemination channels; and by its monetary effect on firms and monetary markets. Store network and assembling exercises of genomic biomarkers analysis frameworks in India, China, and the U.S. are upset because of cross-country lockdowns.
𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4578
Nonetheless, rising instances of ongoing diseases related to COVID-19 contaminations like cardiovascular sickness, stroke, joint inflammation, and others are supposed to drive the development of the genomic biomarker market as a diagnostic instrument. For example, as indicated by an article distributed by the American Heart Association Journal in February 2021, the gamble of having an intense ischemic stroke is expanded in patients who are COVID-19 positive. This is supposed to expand the development of the genomic biomarker market during the gauge time frame.
In addition, the send-off of new items is supposed to drive the genomic biomarker market development. For example, in 2018, Qiagen, a German sub-atomic diagnostic innovation supplier, declared send off of its item GeneRead QIAact Actionable Insights Tumor board for the extension of its item portfolio. This board can identify single nucleotide polymorphism (a genomic biomarker) utilizing just moment volumes of genomic DNA. The discovery of such genomic biomarkers helps in the analysis of lung cancer, prostate growth, melanoma, and other strong growths.
Key Takeaways of the Genomic Biomarker Market:
- The global genomic biomarker market is supposed to show a CAGR of 9.5% over the assessed timeframe. North America is supposed to represent a significant market share trailed by Europe, attributable to rising market techniques like acquisitions, consolidations, and others. For example, in November 2018, Qiagen, declared its association with various associations in the U.K like Health Innovation Manchester, to help the research in genome-based diagnostic devices and accuracy medication improvement. This is supposed to drive the development of the genomic biomarker market.
- Central players working in the global genomic biomarker market incorporate Aepodia, Epigenomics AG, Bio-Rad Laboratories, Inc., Genomic Health, Eurofins Scientific, QIAGEN, Myriad Genetics, Inc., AROS Applied Biotechnology A/S, Liquid Genomics, Inc., F. Hoffmann-La Roche AG, and Thermo Fisher Scientific.
𝐆𝐫𝐚𝐛 𝐭𝐡𝐞 𝐎𝐟𝐟𝐞𝐫 𝐌𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐀𝐛𝐨𝐯𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝐚𝐧𝐝 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟐𝟐-𝟐𝟎𝟐𝟖 @ https://www.coherentmarketinsights.com/promo/buynow/4578
Market Segmentation:
- Global Genomic Biomarker Market, By Indication:
- Oncology
- Cardiovascular diseases
- Neurological diseases
- Others
- Global Genomic Biomarker Market, By End User:
- Hospitals
- Diagnostic & Research Laboratories
- Others
- Global Genomic Biomarker Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- Diagnostic & By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Diagnostic & By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Read Press Release: https://www.coherentmarketinsights.com/press-release/genomic-biomarker-market-3824
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837